La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Emyria Performance dei guadagni passati
Il passato criteri di controllo 0/6
Emyria's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been declining at an average rate of 0.7% per year.
Informazioni chiave
-20.9%
Tasso di crescita degli utili
-1.6%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 31.2% |
| Tasso di crescita dei ricavi | -0.7% |
| Rendimento del capitale proprio | -1,258.1% |
| Margine netto | -613.0% |
| Ultimo aggiornamento sui guadagni | 31 Dec 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02
We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Ripartizione dei ricavi e delle spese
Come Emyria guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -12 | 2 | 0 |
| 30 Sep 23 | 2 | -9 | 2 | 0 |
| 30 Jun 23 | 2 | -5 | 2 | 0 |
| 31 Mar 23 | 2 | -6 | 2 | 1 |
| 31 Dec 22 | 2 | -8 | 2 | 2 |
| 30 Sep 22 | 2 | -7 | 3 | 2 |
| 30 Jun 22 | 2 | -7 | 3 | 1 |
| 31 Mar 22 | 2 | -7 | 3 | 1 |
| 31 Dec 21 | 2 | -6 | 3 | 1 |
| 30 Sep 21 | 2 | -6 | 2 | 1 |
| 30 Jun 21 | 2 | -5 | 2 | 1 |
| 31 Mar 21 | 2 | -5 | 2 | 1 |
| 31 Dec 20 | 2 | -5 | 1 | 1 |
| 30 Sep 20 | 1 | -5 | 2 | 1 |
| 30 Jun 20 | 1 | -5 | 2 | 1 |
| 31 Mar 20 | 1 | -5 | 2 | 1 |
| 31 Dec 19 | 1 | -4 | 2 | 0 |
| 30 Sep 19 | 0 | -3 | 2 | 0 |
| 30 Jun 19 | 0 | -3 | 1 | 0 |
Guadagni di qualità: EMD is currently unprofitable.
Margine di profitto in crescita: EMD is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: EMD is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerare la crescita: Unable to compare EMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: EMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendimento del capitale proprio
ROE elevato: EMD has a negative Return on Equity (-1258.13%), as it is currently unprofitable.